突变模式预测了急性髓性白血病的药物敏感性
Guangrong Qin1, Jin Dai2,3, Sylvia Chien2,3
1Institute for Systems Biology, Seattle, Washington.
概括
急性髓性白血病 (AML) 的遗传突变预测药物反应. 识别这些基因组特征可以为AML患者提供个性化的治疗策略.
科学领域:
- 基因组学就是基因组学.
- 癌症生物学 癌症生物学
- 药物基因组学 药物基因组学
背景情况:
- 急性髓性白血病 (AML) 的特点是显著的遗传异质性,复杂的治疗开发.
- 开发向疗法需要了解药物敏感性和耐药性的基因组基础.
研究的目的:
- 确定基因组特征,用于预测AML的药物反应.
- 阐明药物耐药性和敏感性的遗传基础.
- 为AML研究社区提供有价值的基因组资源.
主要方法:
- 针对性测序和患者衍生的白血病细胞的高通量药物查.
- 单细胞基因组分析分析患者内异质性.
- 机器学习和统计分析以确定预测突变模式.
- 整合大型公共基因组数据集.
主要成果:
- 确定了与对各种治疗剂的敏感性或耐药性相关的特定遗传特征.
- 在AML中发现了五个不同的同时发生的突变组.
- 单细胞分析揭示了具有并发变异的子克隆的存在.
- 突变模式准确地预测了对某些药物类别的敏感性,例如RAS突变AML的MEK抑制剂.
结论:
- 基因突变模式对于预测AML药物反应至关重要.
- 这项研究为基于突变的AML患者的分类提供了一个框架,以指导药物敏感性预测.
- 这些发现支持开发用于AML治疗的精准医学方法.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K